XGN Earnings Prediction
The chart below shows how XGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, XGN sees a -0.51% change in stock price 10 days leading up to the earnings, and a +2.04% change 10 days following the report. On the earnings day itself, the stock moves by +2.48%. This data can give you a slight idea of what to expect for the next quarter's release.
XGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
12.51M
-6.78%
-16.97%
Gross Margin
55.82%
-2.82%
-7.15%
Operating Margin
-37.28%
-1.32%
117.12%
Net Margin
-40.20%
-0.40%
104.16%
EPS
-0.28
-9.68%
75.00%
No Data Available
XGN Earnings Analysis
Exagen Inc. Common Stock Corporation (XGN.O) Earnings Conference Call
Positive
Third Quarter Revenue Analysis: Total revenue for the third quarter was $12.5 million, which includes the net negative impact of $1.2 million third quarter one-time adjustments.
Adjusted EBITDA Improvement: Adjusted EBITDA loss was approximately $4 million for the quarter and we are well on track to deliver a 30% improvement for the full year.
Significant Financial Improvements: We have grown revenue by nearly 30%, expanded ASP by 45%, improved gross margins by over 1300 basis points, reduced OpEx by almost 20%, and improved adjusted EBITDA loss by over 70%.
ASP Improvement Trend: Our trailing 12-month AVISE ASP improved for the 7th consecutive quarter, up to $404 per CTD test, demonstrating the strength of our efforts in growing ASP.
Significant Financial Improvements: We have grown revenue by nearly 30%, expanded ASP by 45%, improved gross margins by over 1300 basis points, reduced OpEx by almost 20%, and improved adjusted EBITDA loss by over 70%.
Negative
Third Quarter Revenue Analysis: Total revenue for the third quarter was $12.5 million, which includes the net negative impact of $1.2 million in one-time adjustments.
One-Time Adjustments Impact: This decrease was primarily due to one-time adjustments recognized in the third quarter which I will expand on shortly.
Gross Margin Comparison: Our gross margin was 55.8% in the third quarter compared to 57.4% in 2023, with one-time adjustments impacting gross margin in the third quarter.
Quarterly Net Loss Analysis: Net loss for the third quarter was $5 million, compared to $11.4 million for the first nine months of 2024, indicating a significant loss despite an improvement of nearly 40% over the same period in 2023.
Adjusted EBITDA Loss Comparison: Our adjusted EBITDA loss was approximately $4 million for the third quarter of 2024 compared to $3.6 million in 2023.
XGN FAQs
How does XGN typically perform around its earnings report dates?
Is Exagen, Inc. (XGN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
XGN Earning Call Sentiment
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
XGN.O
-2.54%Positive
The earnings call revealed strong financial metrics, including record revenue, improved EBITDA loss, and cash flow expectations. Despite operational challenges and regulatory delays, the company's strategic initiatives, like the new product launch and biopharma contracts, indicate growth potential. The Q&A section highlighted optimism around future product launches and capacity expansion, with analysts showing interest in the company's strategies. The increased revenue guidance and cash flow positivity expectation further support a positive sentiment, likely leading to a stock price increase of 2% to 8% over the next two weeks.
